Valuation: Exelixis, Inc.

Market Cap 1.45TCr 1.27TCr 1.21TCr 1.09TCr 2.05TCr 1,38800Cr 2.08TCr 14TCr 5.56TCr 71TCr 5.43TCr 5.32TCr 2,27400Cr P/E 2026 *
18x
P/E 2027 * 14.9x
Enterprise Value 1.37TCr 1.21TCr 1.15TCr 1.03TCr 1.95TCr 1,31600Cr 1.97TCr 14TCr 5.27TCr 67TCr 5.16TCr 5.04TCr 2,15700Cr EV / Sales 2026 *
5.37x
EV / Sales 2027 * 4.42x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day+4.05%
1 week+8.00%
1 month+14.68%
3 months+13.87%
1 week 47.88
Extreme 47.8755
50.33
1 month 45.44
Extreme 45.4435
50.33
Current year 41.02
Extreme 41.0245
50.33
1 year 41.02
Extreme 41.0245
50.33
3 years 41.02
Extreme 41.0245
50.33
5 years 41.02
Extreme 41.0245
50.33
10 years 41.02
Extreme 41.0245
50.33
Manager TitleAgeSince
Chief Executive Officer 65 22/07/2010
Director of Finance/CFO 58 15/07/2015
Chief Operating Officer 63 01/02/2016
Director TitleAgeSince
Director/Board Member 70 01/02/2004
Director/Board Member 82 01/08/2004
Chairman 77 01/01/1998
Change 5-day change 1-year change 3-year change Capi.($)
+4.05%+8.00% - - 1.45TCr
+4.16%-0.36%+49.37%+94.17% 7.45TCr
-0.19%+1.32%+37.20%+83.85% 6.01TCr
-1.51%+2.39%+9.10%+35.15% 4.82TCr
-0.05%+0.37%+41.54%+36.65% 4.43TCr
+0.38%+7.61%+339.53%+641.55% 4.4TCr
+0.18%+0.26%+7.41%+103.45% 4.16TCr
-0.67%+0.17%+7.60%+46.37% 3TCr
+4.77%+6.16%+36.77%+22.78% 2.93TCr
-1.29%-3.55%-20.74%+352.04% 2.49TCr
Average +0.98%+1.18%+56.42%+157.33% 4.41TCr
Weighted average by Cap. +0.96%+1.36%+61.05%+148.01%

Financials

2026 *2027 *
Net sales 255.46Cr 224.96Cr 213.14Cr 192.42Cr 362.66Cr 24TCr 367.35Cr 2.55TCr 981.35Cr 13TCr 959.25Cr 938.33Cr 40TCr 290.61Cr 255.91Cr 242.46Cr 218.89Cr 412.56Cr 28TCr 417.89Cr 2.9TCr 1.12TCr 14TCr 1.09TCr 1.07TCr 46TCr
Net income 82Cr 72Cr 68Cr 62Cr 116.5Cr 7.87TCr 118.01Cr 819.21Cr 315.26Cr 4.02TCr 308.16Cr 301.44Cr 13TCr 101.23Cr 89Cr 84Cr 76Cr 143.72Cr 9.71TCr 145.57Cr 1.01TCr 388.89Cr 4.96TCr 380.13Cr 371.84Cr 16TCr
Net Debt -74Cr -66Cr -62Cr -56Cr -105.69Cr -7.14TCr -107.06Cr -743.16Cr -285.99Cr -3.65TCr -279.55Cr -273.45Cr -12TCr -162.27Cr -142.89Cr -135.39Cr -122.22Cr -230.36Cr -16TCr -233.34Cr -1.62TCr -623.35Cr -7.95TCr -609.31Cr -596.02Cr -26TCr
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change
30/26/30 CHF 50.33 +4.05%
29/26/29 CHF 48.37 -0.42%
28/26/28 CHF 48.57 +1.46%
25/26/25 CHF 47.88 +1.17%
24/26/24 CHF 47.32 +1.54%
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
58.41USD
Average target price
53.93USD
Spread / Average Target
-7.66%

Quarterly revenue - Rate of surprise